Invitrogen™ TRAIL-R2 (DR5) Recombinant Rabbit Monoclonal Antibody (102), PE

Description

Preparation: This antibody was obtained from a rabbit immunized with purified, recombinant Human TRAIL-R2 (DR5) (Met1-Glu182) and conjugated with PE under optimum conditions, the unreacted PE was removed. Storage: This antibody can be stored at 2C-8C for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.